Free Newsletter

  Email address:
   

>> Preview...
Site Search
>> Advanced search...
We're In the News
CCTV-9 BizCHINA Interview

CCTV-9 BizCHINA Pharma Industry
March 10-15, 2008
>> New videos 

China: Dragon Lures Foreign Investors
StartUp Magazine
February, 2008
>> Free Preview

Interfax Interviews
Greg B. Scott
Interfax China
December, 2007

Takara Bio Reports on Cancer Drug Trial in China

publication date: May 5, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Takara Bio Inc. of Japan has begun a collaboration with Tianjin Cancer Institute & Hospital, Tianjin Medical University, under which Tianjin Cancer Institute & Hospital has initiated clinical research of a cancer immunotherapy developed by Takara. The new immunotherapy uses RetroNectin®, Takara’s proprietary recombinant human fibronectin, to expand T-cells. More details...

Stock Symbol: (TSE: 4974)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
Partners






>> Learn more...

Featured Events


May 21, 2008
Beijing, China
Greg Scott Speaking
 
May 28-30, 2008
Shanghai , China
Greg Scott Speaking
 
BIO 2008 Convention
June 16-20, 2008
San Diego, CA
Greg Scott Speaking
 
At BIO 2008
June 16, 2008
BIOCOM | Burrill
Save over $200
Use code BIO-IC2008
Greg Scott Speaking

BIO China Reception
June 17, 2008
BayHelix
BIOCOM | ChinaBio

July 7-8, 2008
Shanghai, China

>> More events...